

HLC007G – Table of Contents

INTRODUCTION	XIX
STUDY GOALS AND OBJECTIVES	XIX
REASONS FOR DOING THE STUDY	XIX
INTENDED AUDIENCE	XX
SCOPE OF REPORT	XX
INFORMATION SOURCES	XXI
ANALYST CREDENTIALS	XXI
RELATED REPORTS	XXII
BCC ONLINE SERVICES	XXII
DISCLAIMER	XXII
SUMMARY	XXIII
REPORT HIGHLIGHTS	XXIV
SUMMARY TABLE PROJECTED U.S. MDK MARKET BY END-USE SEGMENT, THROUGH 2013 (\$ MILLIONS)	XXV
SUMMARY FIGURE PROJECTED U.S. MDK MARKET BY END-USE SEGMENT, 2007- 2013 (\$ MILLIONS)	XXV
THE MDK INDUSTRY	1
WHAT ARE MDKS?	1
ADVANTAGES OF MDKS	2
USES FOR MDKS	2
CLINICAL TESTING	2
Clinical Diagnostic Testing	3
Monitoring	3
Screening	3
Confirmatory Testing	3
RESEARCH	4
HOME USE	4
VETERINARY DIAGNOSIS	4
MARKET SIZE	4
TABLE 1 PROJECTED U.S. MDK MARKET COMPARED WITH THE TOTAL DIAGNOSTIC TESTING INDUSTRY, THROUGH 2013 (\$ BILLIONS)	5
RELATION TO TOTAL TESTING MARKET	5
FIGURE 1 MDK'S RELATIVE SHARE OF U.S. TESTING MARKET PROJECTED, THROUGH 2013 (\$ BILLIONS)	6
ALTERNATIVE METHODS	6
TABLE 2 ALTERNATIVE METHODS TO MDKS AND AREA OF PRIMARY USE	6
Chemical Assay	7
Culture	7
Microscopy	7
Biological Assay	8
Chromatographic Separation	8
MDK APPLICATIONS	8
TABLE 3 SELECTED MDK APPLICATIONS	9

INDUSTRY STRUCTURE	9
REAGENTS	10
DEVICE/CARRIER	10
PACKAGING	10
COMPONENT SUPPLIERS	11
FIGURE 2 COMPONENTS OF AN MDK	11
TABLE 4 SELECTED LISTING OF MDK COMPONENT SUPPLIERS BY AREA OF PARTICIPATION	12
END MARKETS	12
TABLE 5 MDK APPLICATIONS BY END-USE FACILITY	13
CLINICAL TESTING FACILITIES	13
TABLE 6 U.S. CLINICAL TESTING FACILITIES WITH POTENTIAL FOR USING MDKS: CLIA VS. NON-CLIA	14
CLIA-Certified Laboratories	14
Non-CLIA Laboratories/Facilities	14
RESEARCH LABORATORIES	14
HOME-USE MARKET	15
VETERINARY APPLICATIONS	15
TABLE 7 SELECTED LISTING OF ANIMAL TESTING MDKS	16
INTERNAL MARKET FORCES, EXTERNAL MARKET FORCES	16
TRADE PRACTICES	16
Promotion	17
Pricing	17
Sales Tie-ins	17
INDUSTRY CHANNELS OF DISTRIBUTION	17
FIGURE 3 CHANNELS OF DISTRIBUTION FOR MDKS	18
STRATEGIC ALLIANCES	18
ACQUISITIONS	19
TABLE 8 SELECTED COMPANY ACQUISITIONS, 1995–2008	19
TABLE 8 (CONTINUED)	20
STRATEGIES IN CONSUMER ADVERTISING	20
EXTERNAL MARKET FORCES	20
FIGURE 4 EXTERNAL MARKET FACTORS AFFECTING THE MDK INDUSTRY	21
REGULATORY	21
Food and Drug Administration (FDA)	21
Clinical Laboratory Improvement Amendments	22
Clinical Laboratory Improvement ... (Continued)	23
Clinical Laboratory Improvement ... (Continued)	24
TABLE 9 CLIA WAIVED TESTS	25
TABLE 9 (CONTINUED)	26
Good Manufacturing Practice	26
TABLE 10 PERTINENT PARAMETERS OF GMP REGULATIONS AFFECTING MDKS	27
COST CONTAINMENT EFFORTS	27
Diagnosis Related Groups (DRGs)	27

Medicare	28
Third-Party Payers	29
Physician Ownership/Referral Clinical Laboratory Services	29
CHANGES IN THE INCIDENCE OF DISEASE	29
TABLE 11 PREVALENCE OF SELECTED DISEASES IN THE U.S. POPULATION* (THOUSANDS OF CASES)	30
FIGURE 5 U.S. POPULATION BY AGE BRACKET, 2005 AND 2010	31
TRENDS IN POINT-OF-CARE TESTING	31
TABLE 12 SELECTED LISTING OF CURRENTLY MARKETED POC DEVICES	32
TABLE 13 PROJECTED U.S POINT-OF-CARE DEVICE MARKET, THROUGH 2013 (\$ BILLIONS)	33
I-STAT SYSTEM	33
ABAXIS PICCOLO SYSTEM	33
INTERNATIONAL ASPECTS OF MDK MARKET	34
PRESENCE OF U.S. MANUFACTURERS IN THE WORLDWIDE MARKET	34
TECHNOLOGICAL ASPECTS OF MDK INDUSTRY	35
TESTING METHODS	35
TABLE 14 MAJOR MDK APPLICATIONS BY TYPE OF TECHNOLOGY	35
TABLE 14 (CONTINUED)	36
CHEMICAL ANALYSIS	36
ENZYMATIC ANALYSIS	36
IMMUNOLOGICAL ANALYSIS	37
ENZYME IMMUNOASSAY	37
Basic EIA	38
FIGURE 6 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS	38
Alternative EIA Methods	39
SECOND-ANTIBODY PRECIPITATION METHOD	39
DOUBLE-ANTIBODY SANDWICH METHOD	39
REVERSE-SANDWICH METHOD	39
REVERSE-SANDWICH INHIBITION METHOD	39
FLUORESCENCE IMMUNOASSAY	40
Direct FA	40
Indirect FA	40
LATEX AGGLUTINATION	41
RADIOIMMUNOASSAY	41
Limitations to RIA Testing	41
Types of RIA Methods	42
IMMUNOPRECIPITATION/AGGLUTINATION	42
GENE PROBE ANALYSIS	43
Gene Probes	43
Gene Probe Glossary	43
TYPES OF HYBRIDIZATION COMMONLY USED	44
Gel Electrophoresis/Southern Blot Method	45
HYBRIDIZATION IN SOLUTIONS	45
Solid Support Methods	45

DNA ARRAY TECHNOLOGY	45
AMPLIFICATION	46
Importance of Amplification in the Development of Probes	46
TARGET AMPLIFICATION TECHNIQUES	46
Polymerase Chain Reaction Amplification	47
Nucleic Acid Sequence-Based Amplification (NASBA)	48
Strand-Displacement Amplification	48
Transcription-Mediated Amplification	48
PROBE AMPLIFICATION	49
Q-Beta Replicase	49
Ligase Chain Reaction	49
Cycling Probe Technology	50
SIGNAL AMPLIFICATION	50
Branched DNA Assay	50
MDK FEATURES AFFECTING MARKETABILITY	50
RELIABILITY AND ACCURACY	51
RANGE OF MEASUREMENT AND SENSITIVITY	51
STORAGE STABILITY	51
EASE OF USE	52
CLINICAL MDK APPLICATIONS	53
SEGMENTS	53
TABLE 15 PROJECTED U.S. MDK MARKET BY END-USE SEGMENT, THROUGH 2013 (\$ MILLIONS)	53
CLINICAL LABORATORY APPLICATIONS	54
INFECTIOUS DISEASE TESTING	54
TABLE 16 SELECTED LISTING OF BACTERIA FOUND IN CLINICAL SPECIMENS AND THE DISEASES THEY CAUSE	55
TABLE 17 MAJOR VIRAL INFECTIOUS AGENTS	56
Importance of Testing	56
Clinical Testing Methods	57
TYPES OF MDKS FOR INFECTIOUS DISEASE TESTING	58
Immunodiagnostic Kits	58
DipSticks	59
Microbial and Rapid-Test Kits	59
TABLE 18 SELECTED LISTING OF FDA APPROVED INFECTIOUS DISEASE TESTING MDKS BY TYPE OF ASSAY	59
TABLE 18 (CONTINUED)	60
TABLE 18 (CONTINUED)	61
TABLE 18 (CONTINUED)	62
Gene Probe Kits	62
MARKET SIZE	63
TABLE 19 PROJECTED MDKS MARKET FOR INFECTIOUS DISEASE TESTING BY APPLICATION, THROUGH 2013 (\$ MILLIONS)	63
MARKET DYNAMICS	63
HIV/AIDS Testing	64
Leading Market Participants	65

Tuberculosis and Other Mycobacterium Infections	65
MTD-Direct Detection of Mycobacterium Tuberculosis	65
Confirmatory Gene Probe Kit Tests for Mycobacteria Species	66
SEXUALLY TRANSMITTED DISEASES (STDs)	66
Syphilis	66
Gonorrhea	66
TABLE 20 ANNUAL INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., 2006*	67
Chlamydia	68
Human Papillomavirus	68
Genital Herpes	68
STREPTOCOCCI	69
HEPATITIS	69
DRUG TESTING	70
TYPES OF DRUGS	70
MARKET SIZE	70
TABLE 21 PROJECTED U.S. MDK DRUG TESTING MARKET, THROUGH 2013 (\$ MILLIONS)	71
MDK APPLICATIONS IN DRUG TESTING	71
Therapeutic Monitoring	71
Diagnosing Overdoses	72
Differential Diagnosis	72
Detecting Drug Abuse	72
TABLE 22 SELECTED LISTING OF DRUG TESTING MDKS CURRENTLY MARKETED BY COMPANY	73
ALTERNATIVES TO MDKS	74
HOME-DETECTION METHODS	74
TYPES OF DRUG TESTING MDKS	74
HORMONES	75
Diagnostic Benefits of Hormone Analysis	75
Types of Hormone MDK Tests	75
Hypothalamus	76
Pituitary	76
Thyroid	76
Parathyroid	76
Adrenal Glands	77
Pancreas	77
Brain Peptides	77
HORMONE TESTS MARKETED	77
TABLE 23 SELECTED LISTING OF HORMONE MDKS BY COMPANY	78
Market Size	78
TABLE 24 PROJECTED U.S. MDK HORMONE TESTING MARKET, THROUGH 2013 (\$ MILLIONS)	78
ALTERNATIVES TO MDKS	79
CANCER TESTING	79
Incidence of New Cancer Cases Annually	79

TABLE 25	INCIDENCE OF NEW CANCER CASES IN THE U.S., 2006 AND 2007 (PER ANNUM)	80
	Detection of Cancer	80
	MDKs for Cancer Testing	81
TABLE 26	SELECTED LISTING OF CANCER DIAGNOSTICS AND THERAPEUTIC MANAGEMENT MDK TESTS*	81
	Market Size and Structure	81
TABLE 27	PROJECTED U.S. MARKET FOR CANCER DIAGNOSTIC MDKS: NON-RESEARCH TESTING APPLICATIONS, THROUGH 20013 (\$ MILLIONS)	82
	BLOOD/URINE CHEMISTRY TESTING	82
	Market Size and Structure	82
TABLE 28	PROJECTED U.S. BLOOD/URINE CHEMISTRY MDK MARKET, THROUGH 2013 (\$ MILLIONS)	83
	AUTOMATION VERSUS MDKS	83
	POINT-OF-CARE (POC) ANALYTICAL SYSTEMS USING MDKS	84
	TYPES OF MDKS	84
TABLE 29	CLIA APPROVED MDKS FOR BLOOD/URINE CHEMISTRY TESTING BY COMPANY, 2002–2007	84
	TABLE 29 (CONTINUED)	85
	TABLE 29 (CONTINUED)	86
	TABLE 29 (CONTINUED)	87
	TABLE 29 (CONTINUED)	88
	TABLE 29 (CONTINUED)	89
	TABLE 29 (CONTINUED)	90
	TABLE 29 (CONTINUED)	91
	TABLE 29 (CONTINUED)	92
	Dipsticks	92
	EMERGING MDKS FOR CLINICAL TESTING	93
	Biochips	93
	Reporter Genes	93
	Automatic Sequencing	93
	HOME-USE TESTING MARKET	94
	MARKET SIZE AND STRUCTURE	94
TABLE 30	PROJECTED U.S. HOME-USE MDK MARKET BY TYPE OF TEST, THROUGH 2013 (\$ MILLIONS)	94
	HOME-USE MDK MARKET PARTICIPANTS	95
TABLE 31	SELECTED COMPANIES MARKETING HOME-USE MDK TESTS	95
	BY TEST TYPE	95
	TABLE 31 (CONTINUED)	96
	MAJOR HOME-USE MDK SEGMENTS	96
	HOME PREGNANCY AND OVULATION TESTING	96
	Market Size	97
TABLE 32	PROJECTED U.S. HOME-USE PREGNANCY AND OVULATION TESTING MDK MARKET, THROUGH 2013 (\$ MILLIONS)	97

Market Participants	98
GLUCOSE MONITORING	98
Market Size	99
TABLE 33 PROJECTED U.S. HOME-USE GLUCOSE TESTING MDK MARKET, THROUGH 2013 (\$ MILLIONS)	99
CHOLESTEROL TESTING	99
Market Size	99
TABLE 34 PROJECTED U.S. HOME-USE CHOLESTEROL TESTING MDK MARKET, THROUGH 2013 (\$ MILLIONS)	100
HIV/HEPATITIS TESTING	100
FECAL OCCULT BLOOD TESTING	101
Market Size	101
URINARY OCCULT BLOOD/URINARY INFECTION TESTING	102
Urinary Infection Testing	102
DRUG TESTING	102
Market Size	102
Regulatory Environment	103
U.S. RESEARCH APPLICATIONS	104
MARKET STRUCTURE	104
MARKET SIZE	104
TABLE 35 PROJECTED U.S. RESEARCH MDK MARKET, THROUGH 2013 (\$ MILLIONS)	105
RESEARCH AREAS	105
EPIGENETICS	105
PCR-BASED ASSAYS	106
GENE MAPPING	106
Gene Probes	107
Molecular Biology	107
TABLE 36 SELECTED TYPES OF MDKS MARKETED FOR MOLECULAR BIOLOGY RESEARCH	108
TABLE 37 PROJECTED U.S. MOLECULAR DIAGNOSTIC MDK MARKET, THROUGH 2013 (\$ MILLIONS)	108
VETERINARY APPLICATIONS	109
VETERINARY MEDICINE	109
CHANGES IN THE PRACTICE OF DOMESTIC VETERINARY MEDICINE	109
MARKET SIZE AND STRUCTURE	109
TABLE 38 PROJECTED U.S. VETERINARY TESTING MDK MARKET, THROUGH 2013 (\$ MILLIONS)	110
TABLE 39 DEMAND FOR VETERINARY CARE FOR DOMESTIC PETS, THROUGH 2013 (VISITS PER YR/PETS IN MILLIONS)	111
IMPACT OF AUTOMATED VETERINARY SYSTEMS	111
MARKET PARTICIPANTS	111
VETERINARY MDKS	112
FELINE LEUKEMIA VIRUS	112
TABLE 40 SELECTED LISTING OF VETERINARY MDKS AND SUPPLIERS FOR COMPANION ANIMALS—CANINE, FELINE, AVIAN, EQUINE	113

TABLE 41 SELECTED LISTING OF VETERINARY MDKS AND SUPPLIERS FOR LIVESTOCK ANIMALS (AVIAN, BOVINE, SWINE, EQUINE)	114
CANINE HEARTWORM	114
FELINE HEARTWORM	114
FELINE IMMUNODEFICIENCY VIRUS (FIV)	115
CANINE PARVOVIRUS	115
PROGESTERONE	115
JOHNE'S DISEASE	115
CHEMISTRY TESTS	115
APPENDIX I CLIA WAIVED TESTS: 2002–2007	116
TABLE 42 CLIA WAIVED TESTS: 2002–2007	116
TABLE 42 (CONTINUED)	117
TABLE 42 (CONTINUED)	118
TABLE 42 (CONTINUED)	119
TABLE 42 (CONTINUED)	120
TABLE 42 (CONTINUED)	121
TABLE 42 (CONTINUED)	122
TABLE 42 (CONTINUED)	123
TABLE 42 (CONTINUED)	124
TABLE 42 (CONTINUED)	125
TABLE 42 (CONTINUED)	126
TABLE 42 (CONTINUED)	127
TABLE 42 (CONTINUED)	128
TABLE 42 (CONTINUED)	129
TABLE 42 (CONTINUED)	130
TABLE 42 (CONTINUED)	131
TABLE 42 (CONTINUED)	132
TABLE 42 (CONTINUED)	133
TABLE 42 (CONTINUED)	134
TABLE 42 (CONTINUED)	135
APPENDIX II COMPANY PROFILES	136
ABBOTT LABORATORIES	136
ALFA SCIENTIFIC DESIGNS	136
BAYER AG (MILES-BAYER)	137
BECKMAN COULTER	137
BECTON DICKINSON	138
BIOMERIEUX	138
BIO-RAD LABORATORIES	138
GEN-PROBE	138
GENZYME	139
HESKA CORP.	139
HOME ACCESS HEALTH	139
IDEXX LABORATORIES	140
INBIOS INTERNATIONAL	140
INNOVACON (FORMERLY ACON LABORATORIES)	140
INVERNESS MEDICAL INNOVATIONS	140

INVITROGEN	141	
JOHNSON & JOHNSON	141	
LIFESIGN, LLC	142	
PHAMATECH	142	
QIAGEN	143	
QUIDEL	143	
REMEL	144	
ROCHE DIAGNOSTICS	144	
THERMOFISHER SCIENTIFIC	144	
APPENDIX III COMPANIES BY PRODUCT TYPE		145
TABLE 43 COMPANIES BY PRODUCT TYPE	145	
TABLE 43 (CONTINUED)	146	
TABLE 43 (CONTINUED)	147	
APPENDIX IV DIRECTORY OF MDK COMPANIES		148
AMDL, INC.	148	
ABBOTT LABORATORIES	148	
ACCUTECH, LLC	148	
ACON INTERNATIONAL	148	
AERSCHER DIAGNOSTICS	148	
ALFA SCIENTIFIC DESIGNS, INC.	148	
AMERICAN MICROSCAN	149	
AMNISURE INTERNATIONAL, LLC	149	
ANALYTAB PRODUCTS (BIOMERIEUX)	149	
APEX BIOTECHNOLOGY CORP.	149	
APPLIED BIOSYSTEMS	149	
ARMKEL, LLC	149	
BAYER AG	149	
BECKMAN COULTER	150	
BECTON DICKINSON	150	
BETHAM CORP.	150	
BINAX	150	
BIOMERICA, INC.	150	
BIOMERIEUX, INC.	150	
BIO-RAD LABORATORIES, INC.	150	
BIOSAFE MEDICAL TECHNOLOGIES, INC.	151	
BIOSITE	151	
BIOTECX	151	
BIOWHITTAKER, INC.	151	
BOEHRINGER MANNHEIM	151	
CEPHEID	151	
CENOGENICS CORP.	152	
CHEMATICS, INC.	152	
CHIRON CORP.	152	
CHOLESTECH CORP.	152	
CLONTECH LABORATORIES, INC.	152	
CHROMOGENIC MEDIA	152	

CHRONIMED	152
CUNO, INC.	153
DNA TECHNOLOGIES	153
DADE BEHRING, INC.	153
DIAGNOSTIC PRODUCTS	153
ENZO LIFE SCIENCES, INC.	153
EPICENTRE TECHNOLOGIES	153
FILTERTEK, INC.	153
FIRST CHECK DIAGNOSTICS	154
FORT DODGE ANIMAL HEALTH	154
GDS TECHNOLOGY, INC.	154
GEN-PROBE	154
GENZYME DIAGNOSTICS	154
GERMAINE LABORATORIES	154
GI SUPPLY	154
GLAXO SMITHKLINE	154
GLUCO PLUS	155
W.L. GORE AND ASSOCIATES, INC.	155
HARLAN BIOPRODUCTS FOR SCIENCE, INC.	155
HELENA LABORATORIES	155
HENRY SCHEIN, INC.	155
HESKA CORP.	155
HOME ACCESS HEALTH	155
HOME DIAGNOSTICS, INC.	156
ID BIOMEDICAL	156
IDEXX LABORATORIES	156
IMMUNOSTICS, INC.	156
INBIOS INTERNATIONAL, INC.	156
INCYTE	156
INOVA DIAGNOSTICS	156
INNOVACON	157
INTERFLOW TECHNOLOGIES	157
INTERNATIONAL TECHNIDYNE CORP. (ITC)	157
INVERNESS MEDICAL INNOVATIONS	157
INVITROGEN	157
J&S MEDICAL ASSOCIATES, INC.	157
JANT PHARMACAL	158
JOHNSON & JOHNSON	158
KIMBERLY CLARK/BALLARD	158
LIFESIGN, LLC	158
LITMUS CONCEPTS	158
LXN CORP.	158
MATRITECH, INC.	158
MEDICAL ANALYSIS SYSTEMS, INC.	159
MEDISENSE, INC.	159
MEDITEST, INC.	159

MERIDIAN BIOSCIENCE	159
MILLIPORE CORP.	159
MYRIAD GENETICS, INC.	159
NOVAGEN	159
NOVEX	160
ORASURE TECHNOLOGIES	160
PALL CORP.	160
PHAMATECH	160
PHARMANETICS, INC.	160
POLYMEDCO, INC.	160
POLYMER TECHNOLOGY SYSTEMS, INC.	160
PORETICS CORP.	160
PRINCETON BIOMEDITECH CORP.	161
PSYCHEMEDICS CORP.	161
QIAGEN, INC.	161
QUANTUM BIOTECHNOLOGIES, INC.	161
QUIDEL	161
REDWOOD TOXICOLOGY LABORATORY, INC.	161
REMEL, INC.	161
ROCHE DIAGNOSTIC CORP.	162
SA SCIENTIFIC, INC.	162
STC TECHNOLOGIES, INC.	162
SANOFI DIAGNOSTICS PASTEUR, INC.	162
SERADYN	162
SERIM RESEARCH CORP.	162
SIEMENS HEALTHCARE DIAGNOSTICS, INC.	162
SIGMA-ALDRICH	163
SPECTRAL DIAGNOSTICS	163
STANBIO LABORATORY	163
STRATAGENE	163
STRECK	163
SYNBIOTICS	163
SYNTRON BIORESEARCH	163
SYVA/BEHRING DIAGNOSTICS	164
TAIDOC TECHNOLOGY	164
TECO DIAGNOSTICS	164
TETKO, INC.	164
THERASENSE	164
THERMO BIOSTAR, INC.	164
THERMOFISHER SCIENTIFIC	164
UNIPATH	165
WAKO CHEMICALS USA	165
ZEUS SCIENTIFIC, INC.	165

TABLE 1 PROJECTED U.S. MDK MARKET COMPARED WITH THE TOTAL DIAGNOSTIC TESTING INDUSTRY, THROUGH 2013	(\$ BILLIONS)	5
TABLE 2 ALTERNATIVE METHODS TO MDKS AND AREA OF PRIMARY USE		6
TABLE 3 SELECTED MDK APPLICATIONS		9
TABLE 4 SELECTED LISTING OF MDK COMPONENT SUPPLIERS BY AREA OF PARTICIPATION		12
TABLE 5 MDK APPLICATIONS BY END-USE FACILITY		13
TABLE 6 U.S. CLINICAL TESTING FACILITIES WITH POTENTIAL FOR USING MDKS: CLIA VS. NON-CLIA		14
TABLE 7 SELECTED LISTING OF ANIMAL TESTING MDKS		16
TABLE 8 SELECTED COMPANY ACQUISITIONS, 1995–2008		19
TABLE 9 CLIA WAIVED TESTS		25
TABLE 10 PERTINENT PARAMETERS OF GMP REGULATIONS AFFECTING MDKS		27
TABLE 11 PREVALENCE OF SELECTED DISEASES IN THE U.S. POPULATION* (THOUSANDS OF CASES)		30
TABLE 12 SELECTED LISTING OF CURRENTLY MARKETED POC DEVICES		32
TABLE 13 PROJECTED U.S POINT-OF-CARE DEVICE MARKET, THROUGH 2013 (\$ BILLIONS)		33
TABLE 14 MAJOR MDK APPLICATIONS BY TYPE OF TECHNOLOGY		35
TABLE 15 PROJECTED U.S. MDK MARKET BY END-USE SEGMENT, THROUGH 2013 (\$ MILLIONS)		53
TABLE 16 SELECTED LISTING OF BACTERIA FOUND IN CLINICAL SPECIMENS AND THE DISEASES THEY CAUSE		55
TABLE 17 MAJOR VIRAL INFECTIOUS AGENTS		56
TABLE 18 SELECTED LISTING OF FDA APPROVED INFECTIOUS DISEASE TESTING MDKS BY TYPE OF ASSAY		59
TABLE 19 PROJECTED MDKS MARKET FOR INFECTIOUS DISEASE TESTING BY APPLICATION, THROUGH 2013 (\$ MILLIONS)		63
TABLE 20 ANNUAL INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., 2006*		67
TABLE 21 PROJECTED U.S. MDK DRUG TESTING MARKET, THROUGH 2013 (\$ MILLIONS)		71
TABLE 22 SELECTED LISTING OF DRUG TESTING MDKS CURRENTLY MARKETED BY COMPANY		73
TABLE 23 SELECTED LISTING OF HORMONE MDKS BY COMPANY		78
TABLE 24 PROJECTED U.S. MDK HORMONE TESTING MARKET, THROUGH 2013 (\$ MILLIONS)		78
TABLE 25 INCIDENCE OF NEW CANCER CASES IN THE U.S., 2006 AND 2007 (PER ANNUM)		80
TABLE 26 SELECTED LISTING OF CANCER DIAGNOSTICS AND THERAPEUTIC MANAGEMENT MDK TESTS*		81

TABLE 27 PROJECTED U.S. MARKET FOR CANCER DIAGNOSTIC MDKS:
NON-RESEARCH TESTING APPLICATIONS, THROUGH 2013 (\$ MILLIONS)

82

TABLE 28 PROJECTED U.S. BLOOD/URINE CHEMISTRY MDK MARKET,
THROUGH 2013 (\$ MILLIONS) 83

TABLE 29 CLIA APPROVED MDKS FOR BLOOD/URINE CHEMISTRY TESTING
BY COMPANY, 2002–2007 84

TABLE 30 PROJECTED U.S. HOME-USE MDK MARKET BY TYPE OF TEST,
THROUGH 2013 (\$ MILLIONS) 94

TABLE 31 SELECTED COMPANIES MARKETING HOME-USE MDK TESTS BY
TEST TYPE 95

TABLE 32 PROJECTED U.S. HOME-USE PREGNANCY AND OVULATION
TESTING MDK MARKET, THROUGH 2013 (\$ MILLIONS)

97

TABLE 33 PROJECTED U.S. HOME-USE GLUCOSE TESTING MDK MARKET,
THROUGH 2013 (\$ MILLIONS) 99

TABLE 34 PROJECTED U.S. HOME-USE CHOLESTEROL TESTING MDK
MARKET, THROUGH 2013 (\$ MILLIONS) 100

TABLE 35 PROJECTED U.S. RESEARCH MDK MARKET, THROUGH 2013 (\$
MILLIONS) 105

TABLE 36 SELECTED TYPES OF MDKS MARKETED FOR MOLECULAR
BIOLOGY RESEARCH 108

TABLE 37 PROJECTED U.S. MOLECULAR DIAGNOSTIC MDK MARKET,
THROUGH 2013 (\$ MILLIONS) 108

TABLE 38 PROJECTED U.S. VETERINARY TESTING MDK MARKET,
THROUGH 2013 (\$ MILLIONS) 110

TABLE 39 DEMAND FOR VETERINARY CARE FOR DOMESTIC PETS,
THROUGH 2013 (VISITS PER YR/PETS IN MILLIONS) 111

TABLE 40 SELECTED LISTING OF VETERINARY MDKS AND SUPPLIERS FOR
COMPANION ANIMALS—CANINE, FELINE, AVIAN, EQUINE 113

TABLE 41 SELECTED LISTING OF VETERINARY MDKS AND SUPPLIERS FOR
LIVESTOCK ANIMALS (AVIAN, BOVINE, SWINE, EQUINE) 114

TABLE 42 CLIA WAIVED TESTS: 2002–2007 116

TABLE 43 COMPANIES BY PRODUCT TYPE 145

SUMMARY FIGURE PROJECTED U.S. MDK MARKET BY END-USE SEGMENT,
2007- 2013 (\$ MILLIONS) XXV

FIGURE 1 MDK'S RELATIVE SHARE OF U.S. TESTING MARKET PROJECTED,
THROUGH 2013 (\$ BILLIONS) 6

FIGURE 2 COMPONENTS OF AN MDK 11

FIGURE 3 CHANNELS OF DISTRIBUTION FOR MDKS 18

FIGURE 4 EXTERNAL MARKET FACTORS AFFECTING THE MDK INDUSTRY
21

FIGURE 5 U.S. POPULATION BY AGE BRACKET, 2005 AND 2010 31

FIGURE 6 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS 38